Potenziale und Limitationen der Detektion von zirkulierenden Melanomzellen

Zusammenfassung

Die Bestimmung und Charakterisierung zirkulierender Melanomzellen ist ein nicht invasives und komplikationsarmes Verfahren mit dem Potenzial, einen choroidalen Nävus von einem choroidalen Melanom abzugrenzen und frühzeitig einer Therapie zuführen zu können. Zukünftig bietet es die Chance, das therapeutische Ansprechen zu überwachen und bei der Therapieauswahl zu helfen. Es besteht die Hoffnung, weitere Erkenntnisse hinsichtlich des Metastasierungsprozesses zu gewinnen und damit Ansatzpunkte für die Entwicklung zielgerichteter Therapien. In diesem Artikel werden die verschiedenen Techniken der Bestimmung zirkulierender Tumorzellen vorgestellt und ihr Potenzial bzw. Limitationen diskutiert.

Abstract

The detection and characterisation of circulating melanoma cells (CMC) is a non-invasive procedure with a low complication rate and can potentially distinguish choroidal nevi from uveal melanomas and help to initiate early adequate therapy. It has the perspective to select and monitor treatment. This technique may lead to new insights into the metastasis process itself and help to detect specific targets for future therapies. This article introduces the different techniques for CMC detection; their potentials and limitations are discussed.

Schlüsselwörter

Aderhautnävi - uveales Melanom - zirkulierende Melanomzellen - Metastasen

Key words

choroidal nevi - uveal melanoma - circulating melanoma cells - metastasis

• Literatur

• 1 Cristofanilli M, Budd GT, Ellis MJ. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791
• 2 Cohen SJ, Punt CJ, Iannotti N. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221
• 3 De Bono JS, Scher HI, Montgomery RB. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309
• 4 Rack B, Schindlbeck C, Jückstock J. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106: pii:dju066
• 5 Mocellin S, Keilholz U, Rossi CR. et al. Circulating tumor cells: The ‘leukemic phase’ of solid cancers. Trends Mol Med 2006; 12: 130-139
• 6 Attard G, de Bono JS. Utilizing circulating tumor cells: Challenges and pitfalls. Curr Opin Genet Dev 2011; 21: 50-58
• 7 Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene 2016; 35: 1216-1224
• 8 Gallerani G, Fabbri F. Circulating tumor cells in the adenocarcinoma of the esophagus. Int J Mol Sci 2016; 17: pii:E1266
• 9 Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 2012; 18: 148-152
• 10 Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46: 133-149
• 11 Blanco PL, Lim LA, Miyamoto C. et al. Uveal melanoma dormancy: an acceptable clinical endpoint?. Melanoma Res 2012; 22: 334-340
• 12 Tobal K, Sherman LS, Foss AJ. et al. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci 1993; 34: 2622-2625
• 13 Foss AJ, Guille MJ, Occleston NL. et al. The detection of melanoma cells in peripheral blood by reverse transcription. Br J Cancer 1995; 72: 155-159
• 14 Schuster R, Bechrakis NE, Stroux A. et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13: 1171-1178
• 15 Boldin I, Langmann G, Richtig E. et al. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 2005; 15: 503-507
• 16 Callejo SA, Antecka E, Blanco PL. et al. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye (Lond) 2007; 21: 752-759
• 17 Charitoudis G, Schuster R, Joussen AM. et al. Detection of tumour cells in the bloodstream of patients with uveal melanoma: influence of surgical manipulation on the dissemination of tumour cells in the bloodstream. Br J Ophthalmol 2016; 100: 468-472
• 18 Marshall JC, Nantel A, Blanco P. et al. Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis. Clin Exp Metastasis 2007; 24: 353-362
• 19 Mazzini C, Pinzani P, Salvianti F. et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel) 2014; 6: 323-332
• 20 Janssen Diagnostics. CellSearch® Circulating Tumor Cell Control Kit. Im Internet: http://documents.cellsearchctc.com/pdf/e631600011/e631600011_DE.pdf Stand: 09.12.2016
• 21 Terai M, Mu Z, Eschelman DJ. et al. Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine 2015; 2: 1821-1826
• 22 Bidard FC, Madic J, Mariani P. et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014; 134: 1207-1213
• 23 Cools-Lartigue JJ, McCauley CS, Marshall JC. et al. Immunomagnetic isolation and in vitro expanion of human uveal melanoma cell lines. Mol Vis 2008; 14: 50-55
• 24 Li Y, Madigan MC, Lai K. et al. Human uveal melanoma expresses NG2 immunoreactivity. Br J Ophthalmol 2003; 87: 629-632
• 25 Krivacic RT, Ladanyi A, Curry DN. et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004; 101: 10501-10504
• 26 Dong Y, Skelley AM, Merdek KD. et al. Microfluidics and circulating tumor cells. J Mol Diagn 2013; 15: 149-157
• 27 Menyaev YA, Nedosekin DA, Sarimollaoglu M. et al. Optical clearing in photoacoustic flow cytometry. Biomed Opt Express 2013; 4: 3030-3041
• 28 Sarimollaoglu M, Nedosekin DA, Menyaev YA. et al. Nonlinear photoacoustic signal amplification from single targets in absorption background. Photoacoustics 2014; 2: 1-11
• 29 Ulmer A, Beutel J, Süsskind D. et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 2008; 14: 4469-4474
• 30 Tura A, Lüke J, Merz H. et al. Identification of circulating melanoma cells in uveal melanoma patients by dual-marker immunoenrichment. Invest Ophthalmol Vis Sci 2014; 55: 4395-4404
• 31 Tura A, Merz H, Reinsberg M. et al. Analysis of monosomy-3 in immunomagnetically-isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res 2016;
• 32 Torres V, Triozzi P, Eng C. et al. Circulating tumor cells in uveal melanoma. Future Oncol 2011; 7: 101-109
• 33 Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiological aspects. Ophthalmol Clin North Am 2005; 18: 75-84
• 34 Prescher G, Bornfeld N, Hirche H. et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225
• 35 Tschentscher F, Hüsing J, Hölter T. et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584
• 36 Damato B, Eleuteri A, Taktak AF. et al. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011; 30: 285-295
• 37 Abdel-Rahman MH, Cebulla CM, Verma V. et al. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res 2012; 100: 26-31
• 38 Thomas S, Pütter C, Weber S. et al. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer 2012; 106: 1171-1176
• 39 Lüke J, Tura A, Grisanti S. Aktuelle Diagnostik bei choroidalen Nävi. Klin Monatsbl Augenheilkd 2017;
• 40 Blum ES, Yang J, Komatsubara KM. et al. Clinical management of uveal and conjunctival melanoma. Oncology (Williston Park) 2016; 30: 29-32
• 41 Midena E, Parrozzani R. Biopsies in uveal melanoma. Dev Ophthalmol 2012; 49: 81-95
• 42 Eide N, Walaas L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. Acta Ophthalmol 2009; 87: 588-601
• 43 Grixti A, Angi M, Damato BE. et al. Vitreoretinal surgery for complications of choroidal tumor biopsy. Ophthalmology 2014; 121: 2482-2488
• 44 Bande MF, Santiao M, Muinelo-Romay L. et al. Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC Res Notes 2015; 17: 452
• 45 Lake SL, Coupland SE, Taktak AF. et al. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci 2012; 51: 4884-4891
• 46 Sisley K, Rennie IG, Parsons MA. et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19: 22
• 47 Versluis M, de Lange MJ, van Pelt SI. et al. Digital PCR validates 8 q dosage as prognostic tool in uveal melanoma. PLoS One 2015; 10: e0116371
• 48 McLean IW, Saraiva VS, Burnier Jr. MN. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004; 39: 343-350
• 49 Metz CH, Scheulen M, Bornfeld N. et al. Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med 2013; 2: 208-215
• 50 Van Raamsdonk CD, Griewank KG, Crosby MB. et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-2199
• 51 Shoushtari AN, Carvajal RD. Treatment of uveal melanoma. Cancer Treat Res 2016; 167: 281-293
• 52 De Giorgi V, Pinzani P, Salvianti F. et al. Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol 2010; 146: 1120-1124